Lumida
/NSP
⌘K
Insperity Inc

Insperity Inc

NSP
$49.69USD-0.26%-0.13 today

MARKET CAP

1.9B

P/E (TTM)

FWD P/E

DAY RANGE

$49 – $50

52W RANGE

$19
$56

AI Summary

Stalk
StalkMedium

NSP remains in a Stage 2 uptrend above its 200-day SMA despite a Bullish Exhaustion pattern and a slip below the 9- and 20-day EMAs on weakening volume. The confluent support zone around the 50-day SMA and prior lows in the mid-$48–50 range offers the optimal structural entry for pullback participation. Given neutral-to-slightly bearish RSI and EMAs rolling over, execution should be deferred (Stalk) until price shows acceptance at the 50-day SMA. Failure to hold this level would invalidate the medium-term bullish posture and open the way for deeper pullback.

  • Q2 2026 adjusted EBITDA $36M, up 13% YoY via cost management
  • HR Scale rollout to onboard ~6,000 employees within six months
  • Healthcare costs rose 5% YoY, pressuring operating margins
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Insperity, Inc. (NYSE: NSP) is a leading provider of human resources and business performance solutions specifically tailored for small and medium-sized enterprises (SMBs). The company operates as a Professional Employer Organization (PEO), offering comprehensive HR services including payroll, employee benefits, and compliance management, helping businesses optimize their HR functions while focusing on core operations. Insperity is positioned within the growing trend of increasing demand for outsourced HR services, particularly as businesses seek cost-effective and compliant solutions to navigate the complexities of workforce management amidst economic uncertainties.

Bull says

  • Q2 2026 adjusted EBITDA $36M, up 13% YoY via cost management
  • HR Scale rollout to onboard ~6,000 employees within six months
  • Client retention at ~99%, reflecting strong customer loyalty
  • Q2 2026 adjusted EPS $0.34, revenue up 31% YoY
  • AI adoption pilots in 63% of clients enhance service delivery
  • High book-to-price ratio, strong earnings yield, solid liquidity buffer

Bear says

  • Healthcare costs rose 5% YoY, pressuring operating margins
  • Average paid worksite employees down 1.1% YoY, signaling client stagnation
  • Q4 2025 adjusted EPS was -$0.60, highlighting earnings challenges
  • Client attrition at 11%, selective retention may deepen revenue losses
  • Margin recovery plan execution risk amid cost headwinds
  • Weak profitability, momentum and growth factors dampen investor sentiment

Investment themes with NSP

High Dividend Yield -0.51%

Companies paying above-average dividends

AVGO · JPM · XOM

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-17-2026neutral

Transcript signals

Bull points

  • Our sales force demonstrated resiliency and solid productivity in a market that continued to face many economic uncertainties.
  • We expect that the impact of these pricing measures will start to accumulate during the second half of this year and continue into 2026.
  • we are forecasting full-year adjusted EBITDA in a range of $170 million to $205 million.

Bear points

  • These results fell slightly under the low end of our forecasted range by 3 cents per share and $1 million, respectively, primarily due to a continuation of higher than expected benefits costs.
  • Gross profit per worksite employee in Q2 2025 was $240 per month, down from $282 in Q2 of 2024.
  • $8 million related to higher than expected pharmacy costs driven by higher utilization of specialty drugs, such as the GLP-1s, and a related acceleration in the unit cost of pharmacy on a per-script basis due to a change in the mix of prescriptions towards higher-cost drugs.
Read full transcript analysis ›